Pharmaceuticals News and Research

RSS

AMAG Pharmaceuticals provides update on the commercial launch of Feraheme Injection

AMAG Pharmaceuticals, Inc. today provided an update on the commercial launch of Feraheme® (ferumoxytol) Injection for intravenous (IV) use, including preliminary fourth quarter 2009 Feraheme net product revenues estimates, as well as an update on the Company’s international and label expansion efforts.

10 Jan 2010

Selection of therapeutic workshops to be presented at the Twelfth Annual BIO CEO & Investor Conference

“This year’s BIO CEO & Investor Conference will provide a unique forum to showcase therapeutic areas with key catalysts – from new and dynamic therapies to cutting edge investment opportunities,” said Alan Eisenberg, executive vice president of Emerging Companies & Business Development at BIO.

9 Jan 2010

The Jean Coutu Group reports financial results for third-quarter of fiscal year 2010

The Jean Coutu Group (PJC) Inc. (the "Company" or the "Jean Coutu Group") reported its financial results today for the third quarter of fiscal year 2010 ended November 28, 2009.

9 Jan 2010

Key mechanism for systemic delivery of RNAi therapeutics using LNPs discovered

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has discovered a key mechanism related to the systemic delivery of RNAi therapeutics using lipid nanoparticles (LNPs). The new pre-clinical research was presented at the “Advances in Biopharmaceuticals” Keystone Symposium held January 8-13, 2010 in Midway, Utah, and was performed in collaboration with scientists at the Max Planck Institute of Molecular Cell Biology and Genetics.

9 Jan 2010

Arcadia Capital Advisors files intent to purchase remaining CPEX shares at $14 per share

CPEX Pharmaceuticals, Inc. today confirmed that Arcadia Capital Advisors, LLC and its principal Richard Rofé, who hold approximately 12% of outstanding shares, have filed with the Securities and Exchange Commission (SEC) notice of intention of Mr. Rofé to make an unsolicited contingent offer to purchase the remaining shares of common stock of CPEX for $14.00 per share. Mr. Rofé indicated that any offer would require the CPEX Board of Directors to redeem the Rights under CPEX Shareholder Rights Plan.

9 Jan 2010

Acetylon Pharmaceuticals to utilise additional funding in multiple myeloma drug development

Acetylon Pharmaceuticals, Inc. announced today that it has closed on a $2 million investment from a new undisclosed private investor to bring its total financing to $9.25 million. This new investment will convert to stock in the next substantial round of preferred equity financing.

9 Jan 2010

UCF research opens a new exploratory path for Alzheimer's disease

Despite a massive global research effort, many basics of Alzheimer's disease onset remain elusive. This has hampered development of treatments effective during the earliest stages of the disease, when prevention is most likely.

9 Jan 2010

Recent releases in Global Health

A Lancet Comment examines the "grossly insufficient" progress towards meeting the Millennium Development Goal (MDG) of reducing under-5 child mortality. "Accelerated progress can be achieved, even in the poorest environments, through: integrated, evidence-driven, and community-based programmes that focus on addressing the major causes of death, including pneumonia, diarrhoea, newborn disorders, malaria, HIV, and undernutrition; reaching the unreached with a basic package of interventions at large scale and achieving coverage with equity; and using data for action and advocacy," the comment concludes (You et al., 1/9).

9 Jan 2010

Medical Care Technologies plans to focus on new business strategy in 2010

On October 6, 2009, MDCE entered into a non-binding Letter of Intent with Great Union Corporation ("GUC"), a Hong Kong corporation, with the intent to acquire ownership of certain medical care products developed by GUC.

9 Jan 2010

Strativa Pharmaceuticals awards two agency-of-record assignments to HealthSTAR's Centron

HealthSTAR's Centron, a medical communications company, is pleased to announce that they have been awarded two agency-of-record assignments from Strativa Pharmaceuticals, a division of Par Pharmaceutical, Inc.

9 Jan 2010

AIIRA/CCB drug combination provides superior safety and efficacy compared to other fixed-dose combinations

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that a hypertension drug that requires less-frequent dosing than Novartis's Diovan/Tareg (valsartan) would earn 30 percent patient share according to surveyed U.S. cardiologists

9 Jan 2010

NexMed updates corporate activities

NexMed, Inc., a specialty CRO and a developer of products based on the NexACT® technology, today provided an update on ongoing corporate activities and the status of the Company’s NASDAQ listing.

9 Jan 2010

Cancer Research UK scientists named on New Year's Honours list

Several of Cancer Research UK's scientists have been named on this year's New Year's Honours list, as has the government's National Cancer Director and a long-term supporter of the charity.

9 Jan 2010

Green Cross seeks regulatory approval for peramivir in S.Korea

BioCryst Pharmaceuticals, Inc. today announced that it has been informed by its partner, Green Cross Corp., that Green Cross has filed a New Drug Application (NDA) in South Korea to seek regulatory approval for intravenous (i.v.) peramivir to treat patients with influenza.

9 Jan 2010

ChiroCode Institute and Avazzia jointly promote advanced technology devices

ChiroCode Institute and Avazzia will jointly promote advanced technology devices that help chiropractors and other caregivers manage their patients' chronic pain. The Avazzia BEST Pro Sport device combines microcurrent transcutaneous stimulation with somatic bio-feedback to provide improved results while making obsolete existing TENS devices.

9 Jan 2010

Seven new biopharmaceutical companies join PhRMA, Forbes reports

Forbes recently reported that seven new biopharmaceutical companies have now joined the Pharmaceutical Research and Manufacturers of America (PhRMA).

From CSL Ltd 9 Jan 2010

Savient Pharmaceuticals announces filing of KRYSTEXXA BLA resubmission on track

Savient Pharmaceuticals, Inc. provided an update on its activities directed toward the resubmission of its Biologics License Application (BLA) for KRYSTEXXA(TM) (pegloticase) as a treatment for chronic gout in patients refractory to conventional therapy and reaffirmed its belief that it continues to be on track for the filing of the BLA resubmission for KRYSTEXXA in the first quarter of 2010.

9 Jan 2010

Watson Pharmaceuticals files ANDA with FDA seeking approval to market LoSeasonique

Watson Pharmaceuticals, Inc., a leading specialty pharmaceutical company, today confirmed that its subsidiary, Watson Laboratories, Inc., has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market its levonorgestrel and ethinyl estradiol (0.10 mg/0.02 mg) oral contraceptive product prior to the expiration of U.S. Patent No. 7,615,545, which is owned by Duramed Pharmaceuticals, Inc., a subsidiary of Teva Pharmaceutical Industries, Ltd.

9 Jan 2010

TetraLogic Pharmaceuticals commences its TL32711 SMAC mimetic Phase 1 clinical trial

TetraLogic Pharmaceuticals announced today that the Company has completed dosing of the first cohort in a Phase 1 clinical trial of its selective SMAC mimetic, TL32711. The Phase 1 trial is an open-label, dose-escalation study evaluating the safety and tolerability of TL32711 in adults with solid tumors or lymphoma refractory to standard therapies. The study will also assess the pharmacokinetics, pharmacodynamics and anti-tumor activity of TL32711.

8 Jan 2010

Synta Pharmaceuticals announces pricing of public offering of shares

Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced the pricing of an underwritten public offering of 5,555,556 shares of its common stock at a price to the public of $4.50 per share for gross proceeds of approximately $25 million.

8 Jan 2010

Pharmaceuticals News and Research

AMAG Pharmaceuticals provides update on the commercial launch of Feraheme Injection

Selection of therapeutic workshops to be presented at the Twelfth Annual BIO CEO & Investor Conference

The Jean Coutu Group reports financial results for third-quarter of fiscal year 2010

Key mechanism for systemic delivery of RNAi therapeutics using LNPs discovered

Arcadia Capital Advisors files intent to purchase remaining CPEX shares at $14 per share

Acetylon Pharmaceuticals to utilise additional funding in multiple myeloma drug development

UCF research opens a new exploratory path for Alzheimer's disease

Recent releases in Global Health

Medical Care Technologies plans to focus on new business strategy in 2010

Strativa Pharmaceuticals awards two agency-of-record assignments to HealthSTAR's Centron

AIIRA/CCB drug combination provides superior safety and efficacy compared to other fixed-dose combinations

NexMed updates corporate activities

Cancer Research UK scientists named on New Year's Honours list

Green Cross seeks regulatory approval for peramivir in S.Korea

ChiroCode Institute and Avazzia jointly promote advanced technology devices

Seven new biopharmaceutical companies join PhRMA, Forbes reports

Savient Pharmaceuticals announces filing of KRYSTEXXA BLA resubmission on track

Watson Pharmaceuticals files ANDA with FDA seeking approval to market LoSeasonique

TetraLogic Pharmaceuticals commences its TL32711 SMAC mimetic Phase 1 clinical trial

Synta Pharmaceuticals announces pricing of public offering of shares

Oxygen Measurement eBook - Easily Understand Dissolved Oxygen Measurement eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Managing vibration in IVF laboratories

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence